EBMT 2016 | Genetically modified T-cell therapy in multicenter trials
Catherine Bollard
• 4 Apr 2016
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Catherine Bollard, MD, from Children’s National Health System, Washington, D.C., explains some of challenges associated with multicenter trials of genetically modified T-cell immunotherapy, including the standardisation process of managing toxicities observed in patients following T-cell infusion.
